CTSC and bronchiectasis: The cathepsin C inhibitor INS1007, originally developed by AstraZeneca as AZD7986, an orally applicable drug, is currently assessed in bronchiectasis patients over a 24 week treatment period (ClinicalTrials.gov Identifier: NCT03218917).